EUVIMEDEUVIMED entdecken
Crossref

Tailored HER2 ECD mRNA-LNP vaccines boost CD8+ T cell-mediated antitumor immunity for HER2-positive tumor suppression

Kexin Li, Zilin Ma, Xiaoya Li, Xiuping Chi, Ying Zhang, Cong Zhang, Wen Li, Mingyu Cui, Wei Qi, Yating Zhao, Jun Wang, Guogui Sun und 2 weitere

Drug Resistance Updates · 2026-09 · 88 · 101439

DOI: 10.1016/j.drup.2026.101439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-09. Verfasst von Kexin Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Research Center, The Key Laboratory of Tumor Prevention and Precise Diagnosis & Treatment in Hebei Province, the Fourth Hospital of Hebei Medical Uni…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, CD8-Positive T-Lymphocytes, Cancer Vaccines. Die Arbeit nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hebei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HER2-positive tumors persist as a formidable therapeutic challenge despite advances in targeted agents, chemotherapy, and immunotherapy. Recently, messenger RNA (mRNA) vaccines have emerged as promising avenues for the treatment of advanced tumors and their recurrence, although their clinical application remains challenging. Herein, we developed lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA vaccines encoding the modified extracellular domain (ECD) sequence from rat HER2 (rHER2 ECD mRNA-LNP) and human HER2 (hHER2 ECD mRNA-LNP). While both vaccines elicited effective tumor inhibition, the hHER2 ECD mRNA-LNP demonstrated superior prophylactic and therapeutic efficacy in vivo, and successfully induced potent, antigen-restricted cytotoxicity against human patient-derived organoids (PDOs) ex vivo. Mechanistically, it enhances both humoral and T cell responses, and reprograms CD8+ tumor-infiltrating lymphocytes (TILs) by reducing exhaustion, promoting effector maturation, and inducing memory T cells. Specifically, a reduction in naive-like T cell clusters coupled with an elevation in cycling T cell clusters underpins the vaccine's efficacy. Furthermore, HER2 epitope-specific T cell receptor β-chain variable/joining (Trbv/Trbj) combinations and complementarity-determining region 3 (CDR3) motifs were identified as key contributors to the antigen-specific tumoricidal activity. Crucially, combining the hHER2 ECD mRNA-LNP vaccine with programmed cell death-1 (PD-1) immune checkpoint blockade (ICB) achieves superior antitumor efficacy compared to vaccine monotherapy. Moreover, combining the hHER2 ECD mRNA-LNP vaccine with standard chemoradiotherapy effectively potentiates the therapeutic efficacy against HER2-positive tumors. These findings highlight a promising agent for oncology and suggest that modified HER2 ECD mRNA-LNPs represent a viable and highly effective therapeutic strategy against HER2-positive malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesCD8-Positive T-LymphocytesCancer VaccinesHumansAnimalsRNA, MessengerFemaleNanoparticlesRatsLymphocytes, Tumor-InfiltratingmRNA VaccinesNanovaccinesImmunotherapyMiceLipidsCell Line, TumorLiposomes

Stichwörter der Autor:innen

Breast cancerHER2ImmunotherapyLipid nanoparticlemRNA vaccine

Substanzen

Erb-b2 Receptor Tyrosine KinasesCancer VaccinesRNA, MessengerERBB2 protein, humanLipid NanoparticlesmRNA VaccinesNanovaccinesLipidsLiposomes

Autor:innen und Institutionen

  • Research Center, The Key Laboratory of Tumor Prevention and Precise Diagnosis & Treatment in Hebei Province, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China; Department of Clinical Laboratory…
  • Research Center, The Key Laboratory of Tumor Prevention and Precise Diagnosis & Treatment in Hebei Province, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Research Center, The Key Laboratory of Tumor Prevention and Precise Diagnosis & Treatment in Hebei Province, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China; Department of Chemoradiotherapy,…
  • Research Center, The Key Laboratory of Tumor Prevention and Precise Diagnosis & Treatment in Hebei Province, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China; Department of Pharmaceutical Scie…
  • Department of Gastroenterology, the Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of the Breast Surgery, Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei, China.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hebei Province

Zitieren

APA

Li, K., Ma, Z., Li, X., Chi, X., Zhang, Y., Zhang, C., Li, W., Cui, M., Qi, W., Zhao, Y., Wang, J., Sun, G., Zhang, H., & Zhao, L. (2026). Tailored HER2 ECD mRNA-LNP vaccines boost CD8+ T cell-mediated antitumor immunity for HER2-positive tumor suppression. Drug Resistance Updates, 88, 101439. https://doi.org/10.1016/j.drup.2026.101439

Vancouver

Li K, Ma Z, Li X, Chi X, Zhang Y, Zhang C, et al. Tailored HER2 ECD mRNA-LNP vaccines boost CD8+ T cell-mediated antitumor immunity for HER2-positive tumor suppression. Drug Resistance Updates. 2026;88:101439. doi:10.1016/j.drup.2026.101439

BibTeX
@article{Li2026,
  author = {Li, Kexin and Ma, Zilin and Li, Xiaoya and Chi, Xiuping and Zhang, Ying and Zhang, Cong and Li, Wen and Cui, Mingyu and Qi, Wei and Zhao, Yating and Wang, Jun and Sun, Guogui and Zhang, Hongtao and Zhao, Lianmei},
  title = {Tailored HER2 ECD mRNA-LNP vaccines boost CD8+ T cell-mediated antitumor immunity for HER2-positive tumor suppression},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {88},
  pages = {101439},
  doi = {10.1016/j.drup.2026.101439}
}
Kostenlos starten →